Meta-analysis of clinical efficacy and safety of immunotherapy combined with chemotherapy in non-small cell lung cancer
This study aimed to assess the clinical effectiveness and safety of combining immunotherapy with chemotherapy for non-small cell lung cancer.
Saved in:
| Main Authors: | Zhu Wugang, Xu Wenjing, Liu Degan, Wan Lei, Lu Xiaolan |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
De Gruyter
2025-08-01
|
| Series: | Open Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1515/med-2024-1071 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy and safety of immunotherapy or antiangiogenic agent-based treatment strategies versus chemotherapy as first-line treatment for extensive-stage small cell lung cancer: a network meta-analysis
by: Chengjun Wang, et al.
Published: (2025-06-01) -
Determining optimal clinical target volume margins based on microscopic extracapsular extension of metastatic nodes in patients with non-small-cell lung cancer after chemotherapy or chemotherapy combined with immunotherapy
by: Yujiao Zhang, et al.
Published: (2024-11-01) -
Development of a prognostic model for patients with extensive-stage small cell lung cancer undergoing immunotherapy and chemotherapy
by: Yunbin Gao, et al.
Published: (2025-03-01) -
A Meta‐Analysis of Efficacy and Safety of Neoadjuvant Immunotherapy Plus Chemotherapy for Resectable Non‐Small Cell Lung Cancer
by: Xinru Sun, et al.
Published: (2024-10-01) -
Quality of Life and Symptom Burden in Non-Small-Cell Lung Cancer Patients Receiving Second-Line Chemotherapy Compared with Immunotherapy
by: Christos Stylianou, et al.
Published: (2024-11-01)